Gesellschaftsrecht / M&A

IP / IT

Technologie und Digitalisierung

Steuern

Wettbewerb

Regulierung

Temenos

Homburger News

Homburger and Temenos

On February 6, 2025, Temenos announced that it has reached an agreement with Montagu Private Equity for the sale of Multifonds, its fund administration software business, for a total Enterprise Value of around USD 400 m including an earn-out. Multifonds is a leading global provider of fund administration software, serving all asset classes across multiple jurisdictions and helping fund administrators, asset managers, insurance companies and pension funds achieve increased operational efficiency, whilst reducing risk.
The Homburger team is led by Dieter Gericke and Daniel Häusermann (both Corporate / M&amp;A) and included Nicola Togni, Romain Hondius, Thomas Romelli, Luca Ellenberger and Miriam Oelgarth (all Corporate / M&amp;A), Gregor Bühler, Philippe Baumann and Kristina Martinovic (all IP / IT, Technology and Digital Economy), Stefan Oesterhelt, Laetitia Fracheboud and Juliette Buob (all Tax) as well as Richard Stäuber and Christoph Grüninger (both Competition, Regulatory).

Homburger advises Temenos on the sale of Multifonds to Montagu Private Equity

Kapitalmarkt

Arbeitsrecht und Vergütung für Führungskräfte

Bioversys-web-640x140

20250129_Bioversys

On January 29, 2025, BioVersys AG, a clinical-stage biopharmaceutical company developing and commercializing novel antibacterial products for life-threatening infections domiciled in Basel, Switzerland, announced the launch of its Initial Public Offering (IPO) on SIX Swiss Exchange, the publication of the offer price and the start of the bookbuilding process. The IPO comprises a primary offering targeting gross proceeds of CHF 80 m (including an over-allotment option targeting gross proceeds of CHF 5 m). The implied market capitalization of the company, assuming all offered shares are sold in the IPO and the over-allotment option is exercised in full, is approximately CHF 212.9 m. The first day of trading is expected to be February 7, 2025.
BioVersys focuses on identifying, developing and commercializing novel antibacterial products for serious life-threatening infections caused by multi-drug resistant (MDR) bacteria. The Company&#8217;s most advanced R&amp;D programs address nosocomial pneumonia and blood stream infections caused by Acinetobacter baumannii (BV100, phase 3-ready) and tuberculosis (alpibectir, phase 2a). In addition to its domicile in the biotech hub in Basel, Switzerland, BioVersys has operations in in Lille, France, Delaware, United States and Guangzhou, China.
Citigroup Global Markets Limited, UBS AG and Stifel Europe AG are acting as Joint Global Coordinators and Joint Bookrunners on the IPO, Mirabaud &amp; Cie SA and Octavian AG as Selling Agents.
Homburger is advising BioVersys on all aspects of the IPO as lead counsel. The Homburger team is co-led by Dieter Gericke and Lorenzo Togni and includes Thierry Burckhardt, Magda Aref, Simone Schmid, Raphael Linder, Harun Cetin and Leander Etter (all Corporate / M&amp;A and Capital Markets). Luca Dal Molin and Kristina Martinovic (both IP / IT) are providing intellectual property advice, Jeremy Reichlin (Employment and Executive Compensation) is providing employment and executive compensation advice, and Reto Heuberger and Philippe Weber (both Tax) are providing tax advice.

Homburger advises BioVersys AG on its IPO on SIX Swiss Exchange

Siegfried

Homburger and Siegfried

Siegfried and DiNAQOR AG entered into an agreement relating to the acquisition by Siegfried of a 95% stake in DiNAQOR DiNAMIQS AG (DiNAMIQS), a Swiss-based biotechnology company focused on the development and manufacturing of viral vectors for cell and gene therapies. Siegfried will bring DiNAMIQS’ capabilities to commercial scale and establish DiNAMIQS as a best-in-class biotech CDMO for cell and gene therapies. Through this acquisition, Siegfried further expands its footprint in the biologics space and will create significant mid to long-term growth opportunities in a very dynamic market segment.
Homburger acted as counsel to Siegfried. The team included Karin Mattle and Oriana Schöni (both Corporate/M&amp;A), Gregor Bühler and Kristina Martinovic (both IP/IT) as well as Stefan Oesterhelt and Laetitia Fracheboud (both Tax). Daniel Hasler (Corporate/M&amp;A) advised on the transaction as client relationship partner.

Kristina
Martinovic

Homburger advises Temenos on the sale of Multifonds to Montagu Private Equity

Homburger advises BioVersys AG on its IPO on SIX Swiss Exchange

Homburger advised Siegfried on its acquisition of a 95% stake in DiNAMIQS

Join the Team

Kristina Martinovic

Karriere

Sprachen

Zulassung

Teams

KristinaMartinovic

Homburger advises Temenos on the sale of Multifonds to Montagu Private Equity

Homburger advises BioVersys AG on its IPO on SIX Swiss Exchange

Homburger advised Siegfried on its acquisition of a 95% stake in DiNAMIQS

Join the Team

Kristina Martinovic

Karriere

Sprachen

Zulassung

Teams

Kristina
Martinovic